Sunday, April 30, 2023 1:31:31 PM
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study https://meetings.asco.org/abstracts-presentations/219999
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma https://meetings.asco.org/abstracts-presentations/220091
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma https://meetings.asco.org/abstracts-presentations/225839
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma https://meetings.asco.org/abstracts-presentations/225857
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck https://meetings.asco.org/abstracts-presentations/225970
Recent REPL News
- Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:00:04 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:12 AM
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/08/2024 12:45:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 12:06:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:04:11 PM
- Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 07/30/2024 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/19/2024 08:15:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/19/2024 08:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:36:13 PM
- Replimune Announces $100 Million Private Placement Financing • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:51:06 PM
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 01:15:41 PM
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:27:39 PM
- Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 08:17:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 12:06:59 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM